Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Net Income towards Common Stockholders (2019 - 2025)

Historic Net Income towards Common Stockholders for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to -$1.0 million.

  • Cyclerion Therapeutics' Net Income towards Common Stockholders changed N/A to -$1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 3774.15%. This contributed to the annual value of $7.3 million for FY2023, which is 12837.57% up from last year.
  • As of Q3 2025, Cyclerion Therapeutics' Net Income towards Common Stockholders stood at -$1.0 million.
  • In the past 5 years, Cyclerion Therapeutics' Net Income towards Common Stockholders ranged from a high of $13.5 million in Q3 2023 and a low of -$16.2 million during Q2 2021
  • For the 5-year period, Cyclerion Therapeutics' Net Income towards Common Stockholders averaged around -$6.0 million, with its median value being -$5.2 million (2022).
  • Per our database at Business Quant, Cyclerion Therapeutics' Net Income towards Common Stockholders surged by 32128.43% in 2023 and then plummeted by 2080.92% in 2025.
  • Over the past 5 years, Cyclerion Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$14.3 million in 2021, then surged by 79.82% to -$2.9 million in 2022, then skyrocketed by 565.74% to $13.5 million in 2023, then plummeted by 110.27% to -$1.4 million in 2024, then rose by 27.31% to -$1.0 million in 2025.
  • Its Net Income towards Common Stockholders was -$1.0 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$1.5 million in Q1 2025.